| About SMA |
| Annual Scientific Assembly |
| Medallion Level CME/CE |
| Practice Management |
| Personal & Professional Financial Services |
| SMAtips |
| Member Services |
| Physicians In Training |
| SMA Community |
| Site Map |
|
|
|
| |
Viewing the MedEd On-Demand library is available to all registered visitors at no charge. There will be a charge assessed when applicable to request CME credit. CME credit is FREE to SMA Members.
| Type: |
Multimedia |
| Estimated Time of Completion: |
1 hour |
| CME Credit Designation: |
1 AMA PRA Category 1 Credit(s)™
1 Nursing Contact Hour
|
| CME Fee: |
Non-Member: $25.00
Member: Free
MedEd Subscriber: Included with subscription
|
| Commercial Support: |
Support provided by Merck, Pfizer, Inc. |
| Origination Date: |
August 20, 2008 |
| Expiration Date: |
August 20, 2010 |
| The format for this educational activity is developed around the simple concept of capturing a casual conversation between physicians discussing a timely topic. A physician moderator invites one or two key physicians to sit down and talk through a topic asking questions from a very practical, practice-based viewpoint that in return brings forth answers that physicians can immediately apply in their practices with the goal of improved patient health outcomes. The topics are chosen for their importance and impact on medical management and are worthy of extended discussion. |
| |
| Credit Designation/Accreditation: |
The Southern Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™
1 Nursing Contact Hour
. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Southern Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essential Areas and Elements (including the Standards for Commercial Support) and Accreditation Policies.
Southern Medical Association is an approved provider of continuing nursing education by the Alabama State Nurses Association (ASNA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). Southern Medical Association Provider #5-125. This activity qualifies for 1 contact hour.
|
System requirements:
In order to participate in this activity, you will need a sound card and speakers; Internet Explorer 5.5 or Firefox; Flash Player Plugin (v7.0.1.9 or greater); and Adobe Acrobat Reader (required to view printable PDF version). |
Method of Participation:
Participants watch the video presentation, read supplemental materials, and evaluate the activity. A self-assessment test allows participants to test themselves on the knowledge obtained from activity. CME credit may be requested by submitting the CME credit form.
|
|
Jan N. Basile, MD
Director, Primary Care Service Line, Ralph H. Johnson Medical Center, Professor of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Disclosures:
• Grant/Research Support: Boehringer Ingelheim (ONTARGET), NHLBI (ACCORD), Novartis (ACCOMPLISH)
• Consultant: Abbott Laboratories, Boehringer Ingelheim, Daiichi-Sankyo, Forest, Novartis
• Speaker’s Bureau: Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Forest, GSK, Merck, Novartis, Pfizer
Hertzel C. Gerstein, MD, MSc, FRCPC
Endocrinologist and Professor, McMaster University and Hamilton Health Sciences, Director, Division of Endocrinology & Metabolism, Director of Diabetes Care and Research Program, Hamilton, Ontario, Canada.
Disclosures:
Speaker's Bureau: GSK, SanofiAventis, Boehringer Ingleheim, Merck, Eli Lilly
Consultant: GSK, SanofiAventis, Merck, Novo Nordisk, Roche, Eli Lilly, Medtronic
Jeremy Soule, MD
Assistant Professor of Medicine, Division of Endocrinology, Medical University of South Carolina, Chief, Endocrine Section, Ralph H. Johnson VAMC, Charleston, South Carolina.
Disclosures:
• Speaker’s Bureau: Novartis, Sanofi-Aventis
SMA Disclosure Policy and Conflict of Interest Resolution:
It is SMA's policy that all individuals involved with the planning and implementation of the content of an SMA CME/CE activity are required to disclose to the audience (1) any relevant financial relationships with entities producing healthcare goods or services consumed by or used on patients, and (2) unlabeled/unapproved uses of drugs or devices discussed in their presentation. Conflicts of Interest will be resolved prior to the activity and disclosures will be noted on a slide at the beginning of the lectures and in the program information.
|
|
Target Audience:
Primary Care Physicians, Endocrinologists, Cardiologists, and other health care professionals who care for patients with diabetes.
Purpose/Need:
The National Heart, Lung, and Blood Institute of the National Institutes of Health on February 6, 2008 halted the intensive treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. This is a large clinical trial of people with type 2 diabetes at very high risk for myocardial infarction and stroke. This was done because of safety concerns when it was found that patients in the intensive treatment group (A1C blood glucose lowering goal < 6%) had an increased risk of death compared with a less-intensive treatment strategy (A1C goal between 7 and 7.9%). On the other hand, interim results from the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) found no evidence of an increased risk of death among those patients receiving more aggressive treatment to lower blood glucose (treatment A1C goal < 6.5%). Finally, the results of the VA multicenter trial will also be presented at ADA June 2008 and will add to the data base on the proper “intensity” of glucose reduction for optimal clinical outcome.
Learning Objectives:
1. Outline the research investigating the relationship between diabetes and cardiovascular disease (CVD), and review the different treatment strategies that may decrease the risk of CVD for people with diabetes.
2. Discuss the early discontinuation of the Intensive Arm of in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and what we have learned from this observation.
3. Discuss the current findings from the Action in Diabetes and Vascular Disease (ADVANCE) trial and how they affect clinical practice.
4. Discuss the results of the VA multicenter trial and how those results affect clinical care.
5. Develop a treatment protocol and what the appropriate A1C goal should be for optimizing cardiovascular risk in those with diabetes.
Activity Evaluation:
Participants may evaluate this activity by rating statements located on the CME Credit/Evaluation form.
|
You are not currently logged in. To view this CME, please login or register now.
Viewing the MedEd On-Demand library is available to all registered visitors at no charge. There will be a charge assessed when applicable to request CME credit. CME credit is FREE to SMA Members.
| |
 |
You must first login to view this CME.
|
Jan N. Basile, MD |
|
| |
 |
You must first login to view this CME.
|
Hertzel C. Gerstein, MD, MSc, FRCPC |
|
| |
 |
You must first login to view this CME.
|
Jeremy Soule, MD |
|
| |
|
|
|
|
